Ergotamin

Ergotamin
Data klinis


Nama dagang	Cafergot (with caffeine), Ergomar, others
Nama lain	2'-Methyl-5'α-benzyl-12'-hydroxy-3',6',18-trioxoergotaman; 9,10α-Dihydro-12'-hydroxy-2'-methyl-5'α-(phenylmethyl)ergotaman-3',6',18-trione
AHFS/Drugs.com	monograph
Rute pemberian	Oral
Kode ATC	N02CA02(WHO)
Status hukum
Status hukum	AU:S4 (Prescription only) CA:Schedule VI UK:POM (Hanya resep) US:℞-only DEA controlled precursor
Data farmakokinetika
Bioavailabilitas	Intravenous: 100%,^[1] Intramuscular: 47%,^[2] Oral: <1%^[3] (Enhanced by co-administration of caffeine^[1])
Metabolisme	Hepatic^[2]
Waktu paruh eliminasi	2 hours^[2]
Ekskresi	90% biliary^[2]
Pengenal
Nama IUPAC (6aR,9R)-N-((2R,5S,10aS,10bS)-5-Benzyl-10b-hydroxy-2-methyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
Nomor CAS	113-15-5^Y
PubChem CID	8223
IUPHAR/BPS	149
DrugBank	DB00696^Y
ChemSpider	7930^Y
UNII	PR834Q503T
KEGG	D07906^Y
ChEBI	CHEBI:64318^N
ChEMBL	ChEMBL442^Y
Ligan PDB	ERM (PDBe, RCSB PDB)
CompTox Dashboard (EPA)	DTXSID9043774
ECHA InfoCard	100.003.658
Data sifat kimia dan fisik
Rumus	C₃₃H₃₅N₅O₅
Massa molar	581,67 g·mol⁻¹
Model 3D (JSmol)	Gambar interaktif
SMILES C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C
InChI InChI=1S/C33H35N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,15,17,21,25-27,34,42H,7,12-14,16,18H2,1-2H3,(H,35,39)/t21-,25-,26+,27+,32-,33+/m1/s1^Y Key:XCGSFFUVFURLIX-VFGNJEKYSA-N^Y
^NY (what is this?) (verify)

Ergotamin adalah obat yang digunakan untuk meredakan atau mencegah migrain. Obat ergotamin biasanya dapat ditemukan dalam produk obat yang dikombinasikan dengan kafein. Obat ergotamin merupakan vasokonstriktor agonis adrenergik selektif alfa-1.^[4]^[5]

Referensi

1 2 Sanders SW, Haering N, Mosberg H, Jaeger H (1986). "Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing". European Journal of Clinical Pharmacology. 30 (3): 331–334. doi:10.1007/BF00541538. PMID 3732370. S2CID 37538721.
1 2 3 4 Tfelt-Hansen P, Johnson ES (1993). "Ergotamine". Dalam Olesen J, Tfelt-Hansen P, Welch KM (ed.). The Headaches. New York: Raven Press. hlm. 313–22.
↑ Ibraheem JJ, Paalzow L, Tfelt-Hansen P (Desember 1983). "Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers". British Journal of Clinical Pharmacology. 16 (6): 695–699. doi:10.1111/j.1365-2125.1983.tb02243.x. PMC 1428366. PMID 6419759.{{cite journal}}: Pemeliharaan CS1: Tanggal diterjemahkan otomatis (link)
↑ "Ergotamine-Caffeine Oral: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD". www.webmd.com (dalam bahasa Inggris). Diakses tanggal 2023-06-20.
↑ "Ergotamine". go.drugbank.com. Diakses tanggal 2023-06-20.